- Entasis Therapeutics Holdings Inc ETTX stock is up sharply after the journal Nature published an article on the potential of its preclinical candidate ETX0462, which could become the first of a new class of antibiotics.
- ETX0462 is under development for multidrug-resistant Gram-negative and biothreat infections.
- The manuscript details the discovery of ETX0462, highlighting concurrent optimization of biochemical potency and drug penetration into the bacterial cells to identify structural elements critical for antimicrobial activity.
- ETX0462 can permeate bacterial cells through multiple porins, and inhibition of multiple penicillin-binding proteins enzyme subtypes results in a low likelihood of antibiotic resistance.
- Price Action: ETTX shares are up 10.60% at $3.03 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
